The global gastric motility disorder drugs market is witnessing steady growth due to the rising burden of gastrointestinal disorders and the increasing aging population worldwide. According to recent industry analysis, the market was valued at US$ 57.6 Bn in 2023 and is projected to reach US$ 102.7 Bn by the end of 2034, expanding at a CAGR of 5.4% from 2024 to 2034.

The market is gaining momentum as healthcare providers and pharmaceutical companies continue to focus on improving treatment options for digestive disorders that significantly impact quality of life. Increasing awareness regarding gastrointestinal health, advancements in pharmaceutical research, and rising healthcare expenditure are further contributing to the expansion of the gastric motility disorder drugs industry.

Understanding Gastric Motility Disorders

Gastric motility disorders refer to conditions that affect the movement of food through the digestive tract. These disorders occur when the muscles and nerves controlling gastrointestinal movements do not function properly, leading to symptoms such as nausea, bloating, constipation, abdominal pain, vomiting, acid reflux, and difficulty in digestion.

Common gastric motility disorders include:

• Gastroparesis
• Gastroesophageal Reflux Disease (GERD)
• Functional dyspepsia
• Irritable Bowel Syndrome (IBS)
• Dumping syndrome
• Intestinal pseudo-obstruction
• Small intestinal bacterial overgrowth (SIBO)

Drugs developed for these conditions help regulate gastrointestinal hormones, stimulate stomach muscles, reduce acid production, and improve stomach emptying and digestive movement.

The increasing prevalence of digestive disorders across all age groups is driving the demand for effective gastric motility treatments globally.

Rising Incidence of Gastric Disorders Fueling Market Growth

One of the major factors driving the gastric motility disorder drugs market is the growing prevalence of gastrointestinal diseases worldwide. Modern lifestyle habits, poor dietary choices, stress, and sedentary routines are contributing significantly to digestive complications.

According to the World Gastroenterology Organisation, nearly half of the global population experiences some form of gastric disorder, including functional constipation, diarrhea, dyspepsia, and IBS.

Several lifestyle-related factors are contributing to the increase in digestive disorders, such as:

• Low-fiber diets
• Lack of physical activity
• Excessive consumption of processed foods
• High stress levels
• Irregular eating habits
• Frequent travel and routine disruptions
• Overuse of certain medications

The increasing occurrence of gastric disorders has created strong demand for medications that provide symptom relief and improve gastrointestinal functioning. As a result, pharmaceutical companies are actively investing in research and development to introduce advanced therapies with improved efficacy and reduced side effects.

Aging Population Supporting Market Expansion

The rapid rise in the global geriatric population is another major factor contributing to market growth. Aging naturally affects digestive system functioning, including reduced gastric contractions, slower digestion, and weakened gastrointestinal motility.

Older adults are more susceptible to conditions such as GERD, gastroparesis, chronic constipation, and digestive discomfort. According to the National Institutes of Health, aging can significantly impact gastric emptying and gastrointestinal muscle coordination.

Additionally, the United Nations World Social Report 2023 estimates that the global population aged 65 years and above will increase from 761 million in 2021 to nearly 1.6 billion by 2050.

This demographic shift is expected to substantially increase the demand for gastric motility disorder medications over the coming years. Healthcare systems globally are therefore focusing on improving diagnosis, treatment accessibility, and long-term management of gastrointestinal diseases among elderly patients.

Challenges Limiting Market Growth

Despite positive growth prospects, the gastric motility disorder drugs market faces several challenges. Long-term use of certain gastrointestinal medications may result in side effects, including neurological complications, hormonal imbalances, and cardiovascular concerns.

Another challenge is the complexity of gastric motility disorders themselves. The underlying biological mechanisms behind many digestive disorders are still not fully understood, making drug development more difficult and time-consuming.

Additionally, lack of awareness and delayed diagnosis in underdeveloped regions can limit treatment adoption rates. However, pharmaceutical companies are increasingly launching awareness campaigns and educational programs to improve understanding of gastrointestinal health in emerging economies.

North America Leads the Global Market

North America dominated the gastric motility disorder drugs market in 2023 and is expected to maintain its leadership position throughout the forecast period.

Several factors contribute to the region’s dominance:

• High healthcare expenditure
• Strong pharmaceutical research infrastructure
• Early adoption of advanced therapies
• Growing prevalence of gastrointestinal disorders
• Favorable reimbursement systems

The United States represents the largest market within North America due to the strong presence of leading pharmaceutical companies and increasing awareness regarding digestive health.

Meanwhile, Asia Pacific is emerging as a highly promising market. Countries such as China and India are strengthening local pharmaceutical manufacturing capabilities through government reforms and industry incentives. Collaborations between global pharmaceutical companies and regional manufacturers are also improving product distribution and market accessibility.

Competitive Landscape and Key Developments

The global gastric motility disorder drugs market is highly competitive, with leading pharmaceutical companies focusing on product innovation, regulatory approvals, partnerships, and strategic expansions.

Major companies operating in the market include:

• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Janssen Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Boehringer Ingelheim
• Eli Lilly and Company
• Bristol-Myers Squibb
• Daiichi Sankyo Company Limited
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Ferring Pharmaceuticals
• UCB

Recent developments highlight the industry’s focus on innovation and expansion. In February 2024, Takeda received U.S. FDA approval for EOHILIA, the first approved oral treatment for eosinophilic esophagitis. Similarly, Vanda Pharmaceuticals advanced its NDA application for tradipitant, aimed at treating symptoms associated with gastric motility disorders.

Companies are also investing in partnerships and commercialization agreements to strengthen their market presence and improve patient access to therapies.

Future Outlook

The future of the gastric motility disorder drugs market appears promising as rising digestive health concerns, aging populations, and healthcare advancements continue to drive demand.

Growing awareness about gastrointestinal wellness, increasing healthcare investments, and ongoing pharmaceutical innovation are expected to support long-term market expansion. Additionally, emerging economies are likely to create new growth opportunities due to improving healthcare infrastructure and rising access to medical treatments.

As research into gastrointestinal disorders advances, the industry is expected to witness the development of more targeted, safer, and effective therapies that improve patient outcomes and quality of life globally.

 Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com